RxDoctor Payments Data

Shayna Aguilar, NP

Psychiatric/Mental Health · Greencastle, INNPI 1275159485

Payments from drug & device makers

$1,081in general payments, 2019–2025

Across 60 payments — averaging $18.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$223
  • Johnson & Johnson$165
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$159
  • AbbVie$154
  • Supernus Pharmaceuticals, Inc.$125
  • Takeda Pharmaceuticals U.S.A., Inc.$67
  • plus $190 from 7 others

What the payments were for

  • Food & beverage$94287%
  • Education$13913%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$4,533
Medicare patients
40
Services billed
62

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate20$162,415
RexultiBrexpiprazole40$57,819
VraylarCariprazine Hcl30$51,166
CaplytaLumateperone Tosylate14$25,491
BelsomraSuvorexant23$10,109
Aripiprazole60$4,513
Ramelteon11$3,958
Asenapine Maleate18$3,513
Duloxetine Hcl126$3,473
Divalproex Sodium ErDivalproex Sodium23$2,198
Mirtazapine137$1,883
Vilazodone Hcl20$1,496
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$1,467
Clonazepam95$1,264
Bupropion XlBupropion Hcl61$1,073

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$223$57,81940 claims
AbbVieVraylar$154$51,16630 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$159$25,49114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Greencastle

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →